Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADE101 in healthy volunteers
NCT07059312Phase 1Active, not recruiting
- Sponsor
- Jade Biosciences, Inc.
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing JADE101 with Placebo (2 arms). Primary endpoint: Safety and Tolerability of Single Ascending Doses of JADE101 in Healthy Participants at 48 weeks. Started Aug 2025; status: active, not recruiting.
02
Drugs
JADE101
Beyond the preview
Go deeper on NCT07059312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059312.